Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MS Society of Canada to fund multiple sclerosis study
University of Calgary’s Hotchkiss Brain Institute will utilize the funds to study the damage that occurs in MS prior to inflammation. To date, central nervous system (CNS) damage
University of Calgary’s Hotchkiss Brain Institute will utilize the funds to study the damage that occurs in MS prior to inflammation. To date, central nervous system (CNS) damage
ELND005 is used in the treatment of neuropsychiatric disorders such as Alzheimer’s and bipolar. The company plans to initiate a proof of concept, Phase II study in bipolar
The open-label, multinational, Phase 2 clinical study is designed to assess the safety and tolerability of infusions of GALNS at a dose of 2.0 mg/kg/week over a 52-week
Travelan, an over the counter (OTC) product, is used for the prevention of Travellers Diarrhea, by reducing the risk of infection by ETEC, the most common cause of
Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI), which blocks reverse transcriptase, a key enzyme that is used by the HIV virus to replicate. The marketing authorisation of
IPI-145 by Infinity is a potent, oral inhibitor of phosphoinositide-3-kinase (PI3K) delta and gamma, used in the treatment of hematologic cancers and inflammatory conditions. IPI-145 is currently undergoing
Lodotra, used in the treatment of rheumatoid arthritis (RA), is a programmed-release formulation of low dose prednisone, that is developed using SkyePharma’s Geoclock technology in collaboration with Horizon.
Huron Life Sciences’ Click Portal software is believed to help re-engineer specific processes, streamline information flows, provide accurate detailed budgets, and eliminate billing inconsistencies. The new software will
Cabozantinib is a potent, dual inhibitor of MET and VEGFR2. Exelixis and the NCI will carry out a series of clinical trials to assess the safety and efficacy
Eylea, also known VEGF Trap-Eye, is a recombinant fusion protein, consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of